CMPS and MMED remain within a ±8% band through October absent a company-specific readout; the academic trials in today's signals do NOT move listed equities materially.

CMPS and MMED — two publicly traded psychedelic drug companies — are predicted to stay within 8% of their current prices through October, because the university-run studies in the news right now don't affect either company's business. These academic studies aren't tied to products those companies are selling or getting approved. Stock prices move on business milestones, not academic publications.

PAT-MIND, AUD, BA-ketamine are investigator-initiated, not sponsor Phase 3. No revenue or approval catalyst attached. Institutional capital ignores academic data flow.